Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
Top 10 pharmaceutical companies in 2024: S&P Global's latest ratings and rankings
01:57pm, Monday, 19'th Aug 2024
In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comp
5 Dividend Growth Stocks to Buy and Hold Forever
09:30am, Monday, 19'th Aug 2024
Dividend growth stocks often outperform other asset classes over long periods. These five blue-chip companies could form the basis of a rock-solid dividend growth portfolio.
2 Dow Jones Dividend Stocks With Above-Average Yields to Buy Now and Hold for at Least a Decade
05:25am, Sunday, 18'th Aug 2024
The Dow Jones Industrial Average contains shares of 30 companies that lead their respective industries. Now that it no longer sells consumer goods, Johnson & Johnson's dividend growth rate could shift
Why Is Johnson & Johnson (JNJ) Up 2.4% Since Last Earnings Report?
12:35pm, Friday, 16'th Aug 2024
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
The Highest Quality Dividend-Growth Healthcare Stocks
09:30am, Thursday, 15'th Aug 2024
Quality Snapshots evaluate dividend-growth companies based on five quality factors including financial performance, resilience and dividend safety. This healthcare sector overview identifies 26 top qu
Prediction: Johnson & Johnson's Dividend Payouts Will Increase in 2025
08:15am, Thursday, 15'th Aug 2024
24/7 Wall St. Insights Stocks that consistently raise their dividends offer investors huge total return potential.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
07:00am, Thursday, 15'th Aug 2024
Are you starting to get nervous about the frothy stock market and thinking about taking some profits off the table? You're not alone.
J&J to disclose support for $6.5 billion talc settlement
03:41pm, Wednesday, 14'th Aug 2024
Johnson & Johnson is preparing to unveil widespread support in coming days for a $6.48 billion offer to settle tens of thousands of legal actions alleging its Baby Powder and other talc products cause
Exclusive: J&J near disclosing support for talc settlement, sources say
12:25pm, Wednesday, 14'th Aug 2024
Johnson & Johnson is preparing to unveil widespread support in coming days for a $6.48 billion offer to settle tens of thousands of legal actions alleging its Baby Powder and other talc products cause
7 Dependable Dividend Stocks for Long-Term Income
06:44am, Wednesday, 14'th Aug 2024
From a long-term perspective, prolonged and stable returns often lead to dividend stocks. These types of stocks provide constant income and mark strong business fundamentals.
3 Blue-Chip Stocks to Buy on the Dip: August 2024
07:30am, Tuesday, 13'th Aug 2024
Blue-chip stocks are commanding attention from investors looking for stability and reliability amidst a fluctuating market. Typically, these stock market stalwarts are known for their solid financials
J&J has enough support from claimants for $6.5 billion talc settlement: report
07:22pm, Monday, 12'th Aug 2024
Johnson & Johnson is reportedly nearing enough support to finalize a $6.5 billion settlement for lawsuits related to cancer cases linked to its baby powder and other talc products.
6 SWAN Stocks To Own
04:53pm, Monday, 12'th Aug 2024
The world is shrouded in numerous uncertainties. S&P's macro outlook for the next 12 months is pessimistic, pointing to worsening trends in 4 out of 7 risk categories. Whether you are risk-averse or a
J&J has enough support from claimants for $6.5 billion talc settlement - Bloomberg
03:17pm, Monday, 12'th Aug 2024
Johnson & Johnson has cleared a key threshold of support for its proposed $6.5 billion settlement of tens of thousands of lawsuits alleging its baby powder and other talc products caused cancer, accor
10 High-Yield Dividend Aristocrats That Could Be Perfect For What's Coming Next
07:00am, Saturday, 10'th Aug 2024
Market volatility recently hit the 3rd highest levels ever recorded, and extreme fear grips Wall Street. The yen carry trade unwind is likely not over yet; US recession risks remain elevated, and the
